BMED Banca Mediolanum S.p.A.
Banca Mediolanum S.p.A. engages in the provision of various banking products and services in Italy. It offers current accounts; deposits products; and mortgage and personal loans. The company also provides credit cards, debit cards, and prepaid cards; investment products, such as mutual funds, unit linked policies, investment strategies, trading services, asset management services, social security, and bond issues and certificates; and insurance policies, including health and personal, life, serious illness, and autonomy protection, as well as protection assistance, and home and family protection. In addition, it offers SelfyCare Pet for reimbursement of veterinary expenses; SelfyCare Travel for assistance and coverage for risks arising during trips; and SelfyCare LifeProject for a specific life project. Banca Mediolanum S.p.A. founded in 1982 and is headquartered in Basiglio, Italy.…
Industry Peers
Banks - RegionalKey Statistics
About Banca Mediolanum (BIT: BMED)
›
Banca Mediolanum (BIT: BMED) is listed on Borsa Italiana, where its shares trade in EUR. It belongs to the Banks - Regional industry, part of the Financial Services sector, and reports about 4,100 employees.
The shares were at 21.88 EUR on 20 November 2026, up 26.0% over 52 weeks. Its 52-week range is 15.99 EUR to 24.81 EUR: the price is 11.8% below the high and 36.8% above the low.
At a market capitalisation of 16.45B EUR, it trades at 12.6 times trailing earnings and 13.7 times forward earnings. The median trailing P/E of its 20 largest Banks - Regional peers is 10.6, a premium of 19% for BMED. It pays a dividend yielding 5.46% (it pays out 71% of its earnings), against a median of 4.16% among the dividend payers in that peer group.
Banca Mediolanum reports return on equity of 27.5%, an operating margin of 64.2% and revenue up 10.6% year over year.
It holds more cash than debt, a net cash position of 201.00M EUR. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 12 analysts cover the stock, with an average rating of Buy; their mean price target of 26.17 EUR is 19.6% above the current price. The next earnings report is expected on 2 February 2027.